tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Karyopharm backs FY25 revenue view $140M-$155M, consensus $147.08M

Expects FY25 U.S. XPOVIO net product revenue to be in the range of $110M-$120M. The company expects its existing liquidity, including the revenue it expects to generate from XPOVIO net product sales and its license agreements, will be sufficient to fund its planned operations to the maturity of its senior convertible notes due October 2025. Excluding the $24.5M remaining 2025 Notes maturity and its $25M minimum liquidity covenant, the company expects it would have sufficient liquidity to fund planned operations into January 2026. The company, with the assistance of its advisors, including its financial advisor Centerview Partners, is exploring potential financing and strategic alternatives to enhance liquidity and maximize value.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1